Aziza AhmedExecutive Director APAC CMC Regulatory Affairs at Merck
Aziza Ahmed serves as Executive Director and APAC head of Chemistry, Manufacturing & Controls (CMC) for Small Molecules, Biologics & Vaccines, Global Regulatory Affairs & Clinical Safety. Aziza, who joined Merck Sharp and Dohme, in September 2016, has over 20 years of pharmaceutical industry experience with 10 years of focused APAC experience. Her last role in Baxter was as a lead for South Korea, South East Asia and India Country Regulatory Affairs teams at Baxter Healthcare. At the start of her career she has worked in Indian generic companies Cipla and Lupin, authoring dossiers for submission to US, EU and other advanced markets. She is based out of Singapore.
Aziza has led regulatory teams for submissions and approvals of various Pharmaceuticals (Solid Orals, Injectables, Large Volume Parenteral, etc.), Vaccines, Biologics, Blood Based Products, OTC, Vitamins and Medical Devices in her career. She has also led regulatory strategy for Greenfield projects which involved setting up a new manufacturing site in Thailand, Mergers & Acquisitions and mandatory adoption of regulatory filings. Recently, she has been collaborating along with her team with the MSD Innovation hub in Singapore on projects involving robotic automation, use of blockchain and AI to streamline regulatory activities. She has been instrumental in driving summer internship programs with National University of Singapore (NUS) and Nanyang Technological University (NTU).
Aziza is currently active in industry organizations such as EFPIA and ISPE and is a member of DIA. Aziza has an M.S. in Regulatory Science from the University of Maryland, an M.S. in Organic Chemistry from the University of Mumbai, India and a recent Mini MBA from International Management Education, Singapore.